|
2011 Journal Article The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label studyImhof, Laurence, Goldinger, Simone M., Baumann, Katrin, Schad, Karin, French, Lars E., Roethlisberger, Peter and Dummer, Reinhard (2011). The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. Melanoma Research, 21 (1), 80-83. doi: 10.1097/CMR.0b013e328341442d |
|
2010 Conference Publication First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07)Dummer, R., Michielin, O., Seifert, B., Ochsenbein, A. F., Cathomas, R., Schlaeppi, M. R., Simcock, M., Gillessen, S., Goldinger, S. M. and von Moos, R. (2010). First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2010.28.15_suppl.8521 |
|
2010 Conference Publication Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07)Fuerstenberger, G., Boneberg, E., Simcock, M., Dummer, R., Goldinger, S. M., Michielin, O., Seifert, B., Ochsenbein, A. F., Schlaeppi, M. R. and von Moos, R. (2010). Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2010.28.15_suppl.8585 |
|
2009 Journal Article Limited value of <SUP>18</SUP>F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanomaStrobel, K., Bode, B., Dummer, R., Veit-Haibach, P., Fischer, D. R., Imhof, L., Goldinger, S., Steinert, Hans C. and von Schulthess, G. K. (2009). Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 36 (11), 1774-1782. doi: 10.1007/s00259-009-1175-0 |
|
2009 Conference Publication Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)Von Moos, R., Seifert, B., Ochsenbein, A., Cathomas, R., Schlaeppi, M., Gillessen, S., Schuller, J. C., Michielin, O., Goldinger, S. and Dummer, R. (2009). Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07). 15th ECCO/34th ESMO Multidisciplinary Congress, Berlin Germany, Sep 20-24, 2009. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. doi: 10.1016/S1359-6349(09)72059-2 |
|
2007 Journal Article Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligoGoldinger, S. M., Dummer, R., Schmid, P., Burg, G., Seifert, B. and Lauchli, S. (2007). Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. Journal of the European Academy of Dermatology and Venereology, 21 (4), 504-508. doi: 10.1111/j.1468-3083.2006.02016.x |
|
2006 Journal Article Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgarisGoldinger, Simone Maria, Dummer, Reinhard, Schmid, Peter, Vavricka, Mareike Prinz, Burg, Guenter and Laeuchli, Severin (2006). Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris. Dermatology, 213 (2), 134-139. doi: 10.1159/000093852 |
